Publications

Authors:

Stella, Federico; Chiappella, Annalisa; Casadei, Beatrice; Bramanti, Stefania; Ljevar, Silva; Chiusolo, Patrizia; Di Rocco, Alice; Tisi, Maria C.; Carrabba, Matteo G.; Cutini, Ilaria; Martino, Massimo; Dodero, Anna; Bonifazi, Francesca; Santoro, Armando; Sorà, Federica; Botto, Barbara; Barbui, Anna M.; Russo, Domenico; Musso, Maurizio; Grillo, Giovanni; Krampera, Mauro; Olivieri, Jacopo; Ladetto, Marco; Cavallo, Federica; Massaia, Massimo; Arcaini, Luca; Pennisi, Martina; Zinzani, Pier L.; Miceli, Rosalba; Corradini, Paolo

Title:

A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas

Year:

2024

Type of item:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Language:

Inglese

Referee:

No

Name of journal:

BLOOD CANCER DISCOVERY

ISSN of journal:

2643-3230

Page numbers:

318-330

Keyword:

CAR-T; Lymphomas

Short description of contents:

: This real-world prospective observational study across 21 Italian centers (CART-SIE) compares axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) outcomes in 485 relapsed-refractory large B-cell lymphoma patients with baseline characteristics matched by Stabilized Inverse Propensity-Score Weighting. Axi-cel versus tisa-cel had higher all-grade cytokine release syndrome (78.6% vs 89.3%, p=0.0017) and neurotoxicity (9.9% vs 32.2%, p<0.0001), but also superior progression-free survival (PFS) at one year (46.5% vs 34.1%, p=0.0009). Even among patients who failed bridging therapy, axi-cel PFS was superior to tisa-cel (37.5% vs 22.7%, p=0.0059). Differences in overall survival (OS) and high-grade immune toxicities were not significant. The CAR-HEMATOTOX score not only predicted hematologic toxicity but also 1-year survival outcomes (51.5% in CAR-HEMATOTOX high vs. 77.2% in CAR-HEMATOTOX low, p<0.0001). Twenty patients developed second primary malignancies, including two cases of T-cell neoplasms. These findings enable more informed selection of anti-CD19 CAR T-cell therapy balancing bridging, safety and efficacy considerations for individual patients.

Product ID:

145421

Handle IRIS:

11562/1160987

Last Modified:

May 2, 2025

Bibliographic citation:

Stella, Federico; Chiappella, Annalisa; Casadei, Beatrice; Bramanti, Stefania; Ljevar, Silva; Chiusolo, Patrizia; Di Rocco, Alice; Tisi, Maria C.; Carrabba, Matteo G.; Cutini, Ilaria; Martino, Massimo; Dodero, Anna; Bonifazi, Francesca; Santoro, Armando; Sorà, Federica; Botto, Barbara; Barbui, Anna M.; Russo, Domenico; Musso, Maurizio; Grillo, Giovanni; Krampera, Mauro; Olivieri, Jacopo; Ladetto, Marco; Cavallo, Federica; Massaia, Massimo; Arcaini, Luca; Pennisi, Martina; Zinzani, Pier L.; Miceli, Rosalba; Corradini, Paolo, A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas «BLOOD CANCER DISCOVERY» , 2024 , pp. 318-330

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo